Global Nuclear Medicine

Nuclear Medicine Comprehensive Study by Type (Tc-99, I-123/131, In-111, Xe-133, Th-201), Application (Oncology, Cardiology, Neurology, Thyroid, Lymphoma, Others), Procedural Volume Assessment (Diagnostic Procedures, Therapeutic Procedures), End Use (Hospitals, Academic & Research Institutes, Diagnostic & Reference Laboratories, Medical Device Companies) Players and Region - Global Market Outlook to 2027

Nuclear Medicine Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Nuclear Medicine Market Overview:
Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. Nuclear medicine procedures are used in diagnosing and treating certain illnesses. These procedures use radioactive materials called radiopharmaceuticals. Examples of diseases treated with nuclear medicine procedures are hyperthyroidism, thyroid cancer, lymphomas, and bone pain from some types of cancer.

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Historical Period2017-2021
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Alpha Radioimmunotherapy-Based Targeted Cancer Treatment

Market Growth Drivers:
Increasing Incidence and Prevalence of Target Conditions and Initiatives to Lessen the Demand-Supply Gap of Mo-99

Challenges:
Hospital Budget Cuts and High Equipment Prices

Restraints:
Short Half-Life of Radiopharmaceuticals

Opportunities:
Use of Radiopharmaceuticals in Neurological Applications

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Cardinal Health (United States), GE Healthcare (United States), Curium (France), Lantheus Medical Imaging (United States), Bayer AG (Germany), Bracco Imaging (Italy), Eczacıbaşı-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France) and NTP Radioisotopes (South Africa). Additionally, following companies can also be profiled that are part of our coverage like JSC Isotope (Russia), NorthStar Medical Radioisotopes (United States), Eckert & Ziegler (Germany) and Jubilant DraxImage (Canada). Analyst at AMA Research see United States Players to retain maximum share of Global Nuclear Medicine market by 2027. Considering Market by Procedural Volume Assessment, the sub-segment i.e. Diagnostic Procedures will boost the Nuclear Medicine market. Considering Market by End Use, the sub-segment i.e. Hospitals will boost the Nuclear Medicine market.

Latest Market Insights:
In 2019. Curium acquired MAP Medical, which will help it to increase its footprint in Europe with direct access to Nordic and Baltic countries.

What Can be Explored with the Nuclear Medicine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Nuclear Medicine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Nuclear Medicine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Nuclear Medicine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Nuclear Medicine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Nuclear Medicine Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Tc-99
  • I-123/131
  • In-111
  • Xe-133
  • Th-201
By Application
  • Oncology
  • Cardiology
  • Neurology
  • Thyroid
  • Lymphoma
  • Others
By Procedural Volume Assessment
  • Diagnostic Procedures
  • Therapeutic Procedures

By End Use
  • Hospitals
  • Academic & Research Institutes
  • Diagnostic & Reference Laboratories
  • Medical Device Companies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidence and Prevalence of Target Conditions
      • 3.2.2. Initiatives to Lessen the Demand-Supply Gap of Mo-99
    • 3.3. Market Challenges
      • 3.3.1. Hospital Budget Cuts and High Equipment Prices
    • 3.4. Market Trends
      • 3.4.1. Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nuclear Medicine, by Type, Application, Procedural Volume Assessment, End Use and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Nuclear Medicine (Value)
      • 5.2.1. Global Nuclear Medicine by: Type (Value)
        • 5.2.1.1. Tc-99
        • 5.2.1.2. I-123/131
        • 5.2.1.3. In-111
        • 5.2.1.4. Xe-133
        • 5.2.1.5. Th-201
      • 5.2.2. Global Nuclear Medicine by: Application (Value)
        • 5.2.2.1. Oncology
        • 5.2.2.2. Cardiology
        • 5.2.2.3. Neurology
        • 5.2.2.4. Thyroid
        • 5.2.2.5. Lymphoma
        • 5.2.2.6. Others
      • 5.2.3. Global Nuclear Medicine by: Procedural Volume Assessment (Value)
        • 5.2.3.1. Diagnostic Procedures
        • 5.2.3.2. Therapeutic Procedures
      • 5.2.4. Global Nuclear Medicine by: End Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Academic & Research Institutes
        • 5.2.4.3. Diagnostic & Reference Laboratories
        • 5.2.4.4. Medical Device Companies
      • 5.2.5. Global Nuclear Medicine Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Nuclear Medicine (Volume)
      • 5.3.1. Global Nuclear Medicine by: Type (Volume)
        • 5.3.1.1. Tc-99
        • 5.3.1.2. I-123/131
        • 5.3.1.3. In-111
        • 5.3.1.4. Xe-133
        • 5.3.1.5. Th-201
      • 5.3.2. Global Nuclear Medicine by: Application (Volume)
        • 5.3.2.1. Oncology
        • 5.3.2.2. Cardiology
        • 5.3.2.3. Neurology
        • 5.3.2.4. Thyroid
        • 5.3.2.5. Lymphoma
        • 5.3.2.6. Others
      • 5.3.3. Global Nuclear Medicine by: Procedural Volume Assessment (Volume)
        • 5.3.3.1. Diagnostic Procedures
        • 5.3.3.2. Therapeutic Procedures
      • 5.3.4. Global Nuclear Medicine by: End Use (Volume)
        • 5.3.4.1. Hospitals
        • 5.3.4.2. Academic & Research Institutes
        • 5.3.4.3. Diagnostic & Reference Laboratories
        • 5.3.4.4. Medical Device Companies
      • 5.3.5. Global Nuclear Medicine Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Nuclear Medicine (Price)
      • 5.4.1. Global Nuclear Medicine by: Type (Price)
  • 6. Nuclear Medicine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Cardinal Health (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GE Healthcare (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Curium (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Lantheus Medical Imaging (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bayer AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Bracco Imaging (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Eczacıbaşı-Monrol Nuclear Products (Turkey)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Nordion (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Advanced Accelerator Applications (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. NTP Radioisotopes (South Africa)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nuclear Medicine Sale, by Type, Application, Procedural Volume Assessment, End Use and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Nuclear Medicine (Value)
      • 7.2.1. Global Nuclear Medicine by: Type (Value)
        • 7.2.1.1. Tc-99
        • 7.2.1.2. I-123/131
        • 7.2.1.3. In-111
        • 7.2.1.4. Xe-133
        • 7.2.1.5. Th-201
      • 7.2.2. Global Nuclear Medicine by: Application (Value)
        • 7.2.2.1. Oncology
        • 7.2.2.2. Cardiology
        • 7.2.2.3. Neurology
        • 7.2.2.4. Thyroid
        • 7.2.2.5. Lymphoma
        • 7.2.2.6. Others
      • 7.2.3. Global Nuclear Medicine by: Procedural Volume Assessment (Value)
        • 7.2.3.1. Diagnostic Procedures
        • 7.2.3.2. Therapeutic Procedures
      • 7.2.4. Global Nuclear Medicine by: End Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Academic & Research Institutes
        • 7.2.4.3. Diagnostic & Reference Laboratories
        • 7.2.4.4. Medical Device Companies
      • 7.2.5. Global Nuclear Medicine Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Nuclear Medicine (Volume)
      • 7.3.1. Global Nuclear Medicine by: Type (Volume)
        • 7.3.1.1. Tc-99
        • 7.3.1.2. I-123/131
        • 7.3.1.3. In-111
        • 7.3.1.4. Xe-133
        • 7.3.1.5. Th-201
      • 7.3.2. Global Nuclear Medicine by: Application (Volume)
        • 7.3.2.1. Oncology
        • 7.3.2.2. Cardiology
        • 7.3.2.3. Neurology
        • 7.3.2.4. Thyroid
        • 7.3.2.5. Lymphoma
        • 7.3.2.6. Others
      • 7.3.3. Global Nuclear Medicine by: Procedural Volume Assessment (Volume)
        • 7.3.3.1. Diagnostic Procedures
        • 7.3.3.2. Therapeutic Procedures
      • 7.3.4. Global Nuclear Medicine by: End Use (Volume)
        • 7.3.4.1. Hospitals
        • 7.3.4.2. Academic & Research Institutes
        • 7.3.4.3. Diagnostic & Reference Laboratories
        • 7.3.4.4. Medical Device Companies
      • 7.3.5. Global Nuclear Medicine Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Nuclear Medicine (Price)
      • 7.4.1. Global Nuclear Medicine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nuclear Medicine: by Type(USD Million)
  • Table 2. Nuclear Medicine Tc-99 , by Region USD Million (2016-2021)
  • Table 3. Nuclear Medicine I-123/131 , by Region USD Million (2016-2021)
  • Table 4. Nuclear Medicine In-111 , by Region USD Million (2016-2021)
  • Table 5. Nuclear Medicine Xe-133 , by Region USD Million (2016-2021)
  • Table 6. Nuclear Medicine Th-201 , by Region USD Million (2016-2021)
  • Table 7. Nuclear Medicine: by Application(USD Million)
  • Table 8. Nuclear Medicine Oncology , by Region USD Million (2016-2021)
  • Table 9. Nuclear Medicine Cardiology , by Region USD Million (2016-2021)
  • Table 10. Nuclear Medicine Neurology , by Region USD Million (2016-2021)
  • Table 11. Nuclear Medicine Thyroid , by Region USD Million (2016-2021)
  • Table 12. Nuclear Medicine Lymphoma , by Region USD Million (2016-2021)
  • Table 13. Nuclear Medicine Others , by Region USD Million (2016-2021)
  • Table 14. Nuclear Medicine: by Procedural Volume Assessment(USD Million)
  • Table 15. Nuclear Medicine Diagnostic Procedures , by Region USD Million (2016-2021)
  • Table 16. Nuclear Medicine Therapeutic Procedures , by Region USD Million (2016-2021)
  • Table 17. Nuclear Medicine: by End Use(USD Million)
  • Table 18. Nuclear Medicine Hospitals , by Region USD Million (2016-2021)
  • Table 19. Nuclear Medicine Academic & Research Institutes , by Region USD Million (2016-2021)
  • Table 20. Nuclear Medicine Diagnostic & Reference Laboratories , by Region USD Million (2016-2021)
  • Table 21. Nuclear Medicine Medical Device Companies , by Region USD Million (2016-2021)
  • Table 22. South America Nuclear Medicine, by Country USD Million (2016-2021)
  • Table 23. South America Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 24. South America Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 25. South America Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 26. South America Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 27. Brazil Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 28. Brazil Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 29. Brazil Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 30. Brazil Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 31. Argentina Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 32. Argentina Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 33. Argentina Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 34. Argentina Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 35. Rest of South America Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 36. Rest of South America Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 37. Rest of South America Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 38. Rest of South America Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 39. Asia Pacific Nuclear Medicine, by Country USD Million (2016-2021)
  • Table 40. Asia Pacific Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 41. Asia Pacific Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 42. Asia Pacific Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 43. Asia Pacific Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 44. China Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 45. China Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 46. China Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 47. China Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 48. Japan Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 49. Japan Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 50. Japan Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 51. Japan Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 52. India Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 53. India Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 54. India Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 55. India Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 56. South Korea Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 57. South Korea Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 58. South Korea Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 59. South Korea Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 60. Taiwan Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 61. Taiwan Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 62. Taiwan Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 63. Taiwan Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 64. Australia Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 65. Australia Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 66. Australia Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 67. Australia Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 68. Rest of Asia-Pacific Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 69. Rest of Asia-Pacific Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 70. Rest of Asia-Pacific Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 71. Rest of Asia-Pacific Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 72. Europe Nuclear Medicine, by Country USD Million (2016-2021)
  • Table 73. Europe Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 74. Europe Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 75. Europe Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 76. Europe Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 77. Germany Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 78. Germany Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 79. Germany Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 80. Germany Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 81. France Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 82. France Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 83. France Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 84. France Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 85. Italy Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 86. Italy Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 87. Italy Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 88. Italy Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 89. United Kingdom Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 90. United Kingdom Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 91. United Kingdom Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 92. United Kingdom Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 93. Netherlands Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 94. Netherlands Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 95. Netherlands Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 96. Netherlands Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 97. Rest of Europe Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 98. Rest of Europe Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 99. Rest of Europe Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 100. Rest of Europe Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 101. MEA Nuclear Medicine, by Country USD Million (2016-2021)
  • Table 102. MEA Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 103. MEA Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 104. MEA Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 105. MEA Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 106. Middle East Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 107. Middle East Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 108. Middle East Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 109. Middle East Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 110. Africa Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 111. Africa Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 112. Africa Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 113. Africa Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 114. North America Nuclear Medicine, by Country USD Million (2016-2021)
  • Table 115. North America Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 116. North America Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 117. North America Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 118. North America Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 119. United States Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 120. United States Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 121. United States Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 122. United States Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 123. Canada Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 124. Canada Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 125. Canada Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 126. Canada Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 127. Mexico Nuclear Medicine, by Type USD Million (2016-2021)
  • Table 128. Mexico Nuclear Medicine, by Application USD Million (2016-2021)
  • Table 129. Mexico Nuclear Medicine, by Procedural Volume Assessment USD Million (2016-2021)
  • Table 130. Mexico Nuclear Medicine, by End Use USD Million (2016-2021)
  • Table 131. Nuclear Medicine Sales: by Type(K Unit)
  • Table 132. Nuclear Medicine Sales Tc-99 , by Region K Unit (2016-2021)
  • Table 133. Nuclear Medicine Sales I-123/131 , by Region K Unit (2016-2021)
  • Table 134. Nuclear Medicine Sales In-111 , by Region K Unit (2016-2021)
  • Table 135. Nuclear Medicine Sales Xe-133 , by Region K Unit (2016-2021)
  • Table 136. Nuclear Medicine Sales Th-201 , by Region K Unit (2016-2021)
  • Table 137. Nuclear Medicine Sales: by Application(K Unit)
  • Table 138. Nuclear Medicine Sales Oncology , by Region K Unit (2016-2021)
  • Table 139. Nuclear Medicine Sales Cardiology , by Region K Unit (2016-2021)
  • Table 140. Nuclear Medicine Sales Neurology , by Region K Unit (2016-2021)
  • Table 141. Nuclear Medicine Sales Thyroid , by Region K Unit (2016-2021)
  • Table 142. Nuclear Medicine Sales Lymphoma , by Region K Unit (2016-2021)
  • Table 143. Nuclear Medicine Sales Others , by Region K Unit (2016-2021)
  • Table 144. Nuclear Medicine Sales: by Procedural Volume Assessment(K Unit)
  • Table 145. Nuclear Medicine Sales Diagnostic Procedures , by Region K Unit (2016-2021)
  • Table 146. Nuclear Medicine Sales Therapeutic Procedures , by Region K Unit (2016-2021)
  • Table 147. Nuclear Medicine Sales: by End Use(K Unit)
  • Table 148. Nuclear Medicine Sales Hospitals , by Region K Unit (2016-2021)
  • Table 149. Nuclear Medicine Sales Academic & Research Institutes , by Region K Unit (2016-2021)
  • Table 150. Nuclear Medicine Sales Diagnostic & Reference Laboratories , by Region K Unit (2016-2021)
  • Table 151. Nuclear Medicine Sales Medical Device Companies , by Region K Unit (2016-2021)
  • Table 152. South America Nuclear Medicine Sales, by Country K Unit (2016-2021)
  • Table 153. South America Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 154. South America Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 155. South America Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 156. South America Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 157. Brazil Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 158. Brazil Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 159. Brazil Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 160. Brazil Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 161. Argentina Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 162. Argentina Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 163. Argentina Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 164. Argentina Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 165. Rest of South America Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 166. Rest of South America Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 167. Rest of South America Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 168. Rest of South America Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 169. Asia Pacific Nuclear Medicine Sales, by Country K Unit (2016-2021)
  • Table 170. Asia Pacific Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 171. Asia Pacific Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 172. Asia Pacific Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 173. Asia Pacific Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 174. China Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 175. China Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 176. China Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 177. China Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 178. Japan Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 179. Japan Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 180. Japan Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 181. Japan Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 182. India Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 183. India Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 184. India Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 185. India Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 186. South Korea Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 187. South Korea Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 188. South Korea Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 189. South Korea Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 190. Taiwan Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 191. Taiwan Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 192. Taiwan Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 193. Taiwan Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 194. Australia Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 195. Australia Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 196. Australia Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 197. Australia Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 198. Rest of Asia-Pacific Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 199. Rest of Asia-Pacific Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 200. Rest of Asia-Pacific Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 201. Rest of Asia-Pacific Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 202. Europe Nuclear Medicine Sales, by Country K Unit (2016-2021)
  • Table 203. Europe Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 204. Europe Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 205. Europe Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 206. Europe Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 207. Germany Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 208. Germany Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 209. Germany Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 210. Germany Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 211. France Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 212. France Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 213. France Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 214. France Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 215. Italy Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 216. Italy Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 217. Italy Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 218. Italy Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 219. United Kingdom Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 220. United Kingdom Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 221. United Kingdom Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 222. United Kingdom Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 223. Netherlands Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 224. Netherlands Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 225. Netherlands Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 226. Netherlands Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 227. Rest of Europe Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 228. Rest of Europe Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 229. Rest of Europe Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 230. Rest of Europe Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 231. MEA Nuclear Medicine Sales, by Country K Unit (2016-2021)
  • Table 232. MEA Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 233. MEA Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 234. MEA Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 235. MEA Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 236. Middle East Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 237. Middle East Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 238. Middle East Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 239. Middle East Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 240. Africa Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 241. Africa Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 242. Africa Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 243. Africa Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 244. North America Nuclear Medicine Sales, by Country K Unit (2016-2021)
  • Table 245. North America Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 246. North America Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 247. North America Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 248. North America Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 249. United States Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 250. United States Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 251. United States Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 252. United States Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 253. Canada Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 254. Canada Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 255. Canada Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 256. Canada Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 257. Mexico Nuclear Medicine Sales, by Type K Unit (2016-2021)
  • Table 258. Mexico Nuclear Medicine Sales, by Application K Unit (2016-2021)
  • Table 259. Mexico Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2016-2021)
  • Table 260. Mexico Nuclear Medicine Sales, by End Use K Unit (2016-2021)
  • Table 261. Nuclear Medicine: by Type(USD/Units)
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Nuclear Medicine: by Type(USD Million)
  • Table 273. Nuclear Medicine Tc-99 , by Region USD Million (2022-2027)
  • Table 274. Nuclear Medicine I-123/131 , by Region USD Million (2022-2027)
  • Table 275. Nuclear Medicine In-111 , by Region USD Million (2022-2027)
  • Table 276. Nuclear Medicine Xe-133 , by Region USD Million (2022-2027)
  • Table 277. Nuclear Medicine Th-201 , by Region USD Million (2022-2027)
  • Table 278. Nuclear Medicine: by Application(USD Million)
  • Table 279. Nuclear Medicine Oncology , by Region USD Million (2022-2027)
  • Table 280. Nuclear Medicine Cardiology , by Region USD Million (2022-2027)
  • Table 281. Nuclear Medicine Neurology , by Region USD Million (2022-2027)
  • Table 282. Nuclear Medicine Thyroid , by Region USD Million (2022-2027)
  • Table 283. Nuclear Medicine Lymphoma , by Region USD Million (2022-2027)
  • Table 284. Nuclear Medicine Others , by Region USD Million (2022-2027)
  • Table 285. Nuclear Medicine: by Procedural Volume Assessment(USD Million)
  • Table 286. Nuclear Medicine Diagnostic Procedures , by Region USD Million (2022-2027)
  • Table 287. Nuclear Medicine Therapeutic Procedures , by Region USD Million (2022-2027)
  • Table 288. Nuclear Medicine: by End Use(USD Million)
  • Table 289. Nuclear Medicine Hospitals , by Region USD Million (2022-2027)
  • Table 290. Nuclear Medicine Academic & Research Institutes , by Region USD Million (2022-2027)
  • Table 291. Nuclear Medicine Diagnostic & Reference Laboratories , by Region USD Million (2022-2027)
  • Table 292. Nuclear Medicine Medical Device Companies , by Region USD Million (2022-2027)
  • Table 293. South America Nuclear Medicine, by Country USD Million (2022-2027)
  • Table 294. South America Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 295. South America Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 296. South America Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 297. South America Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 298. Brazil Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 299. Brazil Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 300. Brazil Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 301. Brazil Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 302. Argentina Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 303. Argentina Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 304. Argentina Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 305. Argentina Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 306. Rest of South America Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 307. Rest of South America Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 308. Rest of South America Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 309. Rest of South America Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 310. Asia Pacific Nuclear Medicine, by Country USD Million (2022-2027)
  • Table 311. Asia Pacific Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 312. Asia Pacific Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 313. Asia Pacific Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 314. Asia Pacific Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 315. China Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 316. China Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 317. China Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 318. China Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 319. Japan Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 320. Japan Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 321. Japan Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 322. Japan Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 323. India Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 324. India Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 325. India Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 326. India Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 327. South Korea Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 328. South Korea Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 329. South Korea Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 330. South Korea Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 331. Taiwan Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 332. Taiwan Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 333. Taiwan Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 334. Taiwan Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 335. Australia Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 336. Australia Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 337. Australia Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 338. Australia Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 339. Rest of Asia-Pacific Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 340. Rest of Asia-Pacific Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 341. Rest of Asia-Pacific Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 342. Rest of Asia-Pacific Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 343. Europe Nuclear Medicine, by Country USD Million (2022-2027)
  • Table 344. Europe Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 345. Europe Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 346. Europe Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 347. Europe Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 348. Germany Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 349. Germany Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 350. Germany Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 351. Germany Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 352. France Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 353. France Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 354. France Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 355. France Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 356. Italy Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 357. Italy Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 358. Italy Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 359. Italy Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 360. United Kingdom Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 361. United Kingdom Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 362. United Kingdom Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 363. United Kingdom Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 364. Netherlands Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 365. Netherlands Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 366. Netherlands Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 367. Netherlands Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 368. Rest of Europe Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 369. Rest of Europe Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 370. Rest of Europe Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 371. Rest of Europe Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 372. MEA Nuclear Medicine, by Country USD Million (2022-2027)
  • Table 373. MEA Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 374. MEA Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 375. MEA Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 376. MEA Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 377. Middle East Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 378. Middle East Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 379. Middle East Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 380. Middle East Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 381. Africa Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 382. Africa Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 383. Africa Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 384. Africa Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 385. North America Nuclear Medicine, by Country USD Million (2022-2027)
  • Table 386. North America Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 387. North America Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 388. North America Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 389. North America Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 390. United States Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 391. United States Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 392. United States Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 393. United States Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 394. Canada Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 395. Canada Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 396. Canada Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 397. Canada Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 398. Mexico Nuclear Medicine, by Type USD Million (2022-2027)
  • Table 399. Mexico Nuclear Medicine, by Application USD Million (2022-2027)
  • Table 400. Mexico Nuclear Medicine, by Procedural Volume Assessment USD Million (2022-2027)
  • Table 401. Mexico Nuclear Medicine, by End Use USD Million (2022-2027)
  • Table 402. Nuclear Medicine Sales: by Type(K Unit)
  • Table 403. Nuclear Medicine Sales Tc-99 , by Region K Unit (2022-2027)
  • Table 404. Nuclear Medicine Sales I-123/131 , by Region K Unit (2022-2027)
  • Table 405. Nuclear Medicine Sales In-111 , by Region K Unit (2022-2027)
  • Table 406. Nuclear Medicine Sales Xe-133 , by Region K Unit (2022-2027)
  • Table 407. Nuclear Medicine Sales Th-201 , by Region K Unit (2022-2027)
  • Table 408. Nuclear Medicine Sales: by Application(K Unit)
  • Table 409. Nuclear Medicine Sales Oncology , by Region K Unit (2022-2027)
  • Table 410. Nuclear Medicine Sales Cardiology , by Region K Unit (2022-2027)
  • Table 411. Nuclear Medicine Sales Neurology , by Region K Unit (2022-2027)
  • Table 412. Nuclear Medicine Sales Thyroid , by Region K Unit (2022-2027)
  • Table 413. Nuclear Medicine Sales Lymphoma , by Region K Unit (2022-2027)
  • Table 414. Nuclear Medicine Sales Others , by Region K Unit (2022-2027)
  • Table 415. Nuclear Medicine Sales: by Procedural Volume Assessment(K Unit)
  • Table 416. Nuclear Medicine Sales Diagnostic Procedures , by Region K Unit (2022-2027)
  • Table 417. Nuclear Medicine Sales Therapeutic Procedures , by Region K Unit (2022-2027)
  • Table 418. Nuclear Medicine Sales: by End Use(K Unit)
  • Table 419. Nuclear Medicine Sales Hospitals , by Region K Unit (2022-2027)
  • Table 420. Nuclear Medicine Sales Academic & Research Institutes , by Region K Unit (2022-2027)
  • Table 421. Nuclear Medicine Sales Diagnostic & Reference Laboratories , by Region K Unit (2022-2027)
  • Table 422. Nuclear Medicine Sales Medical Device Companies , by Region K Unit (2022-2027)
  • Table 423. South America Nuclear Medicine Sales, by Country K Unit (2022-2027)
  • Table 424. South America Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 425. South America Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 426. South America Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 427. South America Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 428. Brazil Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 429. Brazil Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 430. Brazil Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 431. Brazil Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 432. Argentina Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 433. Argentina Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 434. Argentina Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 435. Argentina Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 436. Rest of South America Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 437. Rest of South America Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 438. Rest of South America Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 439. Rest of South America Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 440. Asia Pacific Nuclear Medicine Sales, by Country K Unit (2022-2027)
  • Table 441. Asia Pacific Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 442. Asia Pacific Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 443. Asia Pacific Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 444. Asia Pacific Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 445. China Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 446. China Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 447. China Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 448. China Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 449. Japan Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 450. Japan Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 451. Japan Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 452. Japan Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 453. India Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 454. India Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 455. India Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 456. India Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 457. South Korea Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 458. South Korea Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 459. South Korea Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 460. South Korea Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 461. Taiwan Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 462. Taiwan Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 463. Taiwan Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 464. Taiwan Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 465. Australia Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 466. Australia Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 467. Australia Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 468. Australia Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 469. Rest of Asia-Pacific Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 470. Rest of Asia-Pacific Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 471. Rest of Asia-Pacific Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 472. Rest of Asia-Pacific Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 473. Europe Nuclear Medicine Sales, by Country K Unit (2022-2027)
  • Table 474. Europe Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 475. Europe Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 476. Europe Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 477. Europe Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 478. Germany Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 479. Germany Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 480. Germany Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 481. Germany Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 482. France Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 483. France Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 484. France Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 485. France Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 486. Italy Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 487. Italy Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 488. Italy Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 489. Italy Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 490. United Kingdom Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 491. United Kingdom Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 492. United Kingdom Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 493. United Kingdom Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 494. Netherlands Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 495. Netherlands Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 496. Netherlands Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 497. Netherlands Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 498. Rest of Europe Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 499. Rest of Europe Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 500. Rest of Europe Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 501. Rest of Europe Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 502. MEA Nuclear Medicine Sales, by Country K Unit (2022-2027)
  • Table 503. MEA Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 504. MEA Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 505. MEA Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 506. MEA Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 507. Middle East Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 508. Middle East Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 509. Middle East Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 510. Middle East Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 511. Africa Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 512. Africa Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 513. Africa Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 514. Africa Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 515. North America Nuclear Medicine Sales, by Country K Unit (2022-2027)
  • Table 516. North America Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 517. North America Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 518. North America Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 519. North America Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 520. United States Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 521. United States Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 522. United States Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 523. United States Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 524. Canada Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 525. Canada Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 526. Canada Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 527. Canada Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 528. Mexico Nuclear Medicine Sales, by Type K Unit (2022-2027)
  • Table 529. Mexico Nuclear Medicine Sales, by Application K Unit (2022-2027)
  • Table 530. Mexico Nuclear Medicine Sales, by Procedural Volume Assessment K Unit (2022-2027)
  • Table 531. Mexico Nuclear Medicine Sales, by End Use K Unit (2022-2027)
  • Table 532. Nuclear Medicine: by Type(USD/Units)
  • Table 533. Research Programs/Design for This Report
  • Table 534. Key Data Information from Secondary Sources
  • Table 535. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nuclear Medicine: by Type USD Million (2016-2021)
  • Figure 5. Global Nuclear Medicine: by Application USD Million (2016-2021)
  • Figure 6. Global Nuclear Medicine: by Procedural Volume Assessment USD Million (2016-2021)
  • Figure 7. Global Nuclear Medicine: by End Use USD Million (2016-2021)
  • Figure 8. South America Nuclear Medicine Share (%), by Country
  • Figure 9. Asia Pacific Nuclear Medicine Share (%), by Country
  • Figure 10. Europe Nuclear Medicine Share (%), by Country
  • Figure 11. MEA Nuclear Medicine Share (%), by Country
  • Figure 12. North America Nuclear Medicine Share (%), by Country
  • Figure 13. Global Nuclear Medicine: by Type K Unit (2016-2021)
  • Figure 14. Global Nuclear Medicine: by Application K Unit (2016-2021)
  • Figure 15. Global Nuclear Medicine: by Procedural Volume Assessment K Unit (2016-2021)
  • Figure 16. Global Nuclear Medicine: by End Use K Unit (2016-2021)
  • Figure 17. South America Nuclear Medicine Share (%), by Country
  • Figure 18. Asia Pacific Nuclear Medicine Share (%), by Country
  • Figure 19. Europe Nuclear Medicine Share (%), by Country
  • Figure 20. MEA Nuclear Medicine Share (%), by Country
  • Figure 21. North America Nuclear Medicine Share (%), by Country
  • Figure 22. Global Nuclear Medicine: by Type USD/Units (2016-2021)
  • Figure 23. Global Nuclear Medicine share by Players 2021 (%)
  • Figure 24. Global Nuclear Medicine share by Players (Top 3) 2021(%)
  • Figure 25. Global Nuclear Medicine share by Players (Top 5) 2021(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Cardinal Health (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cardinal Health (United States) Revenue: by Geography 2021
  • Figure 29. GE Healthcare (United States) Revenue, Net Income and Gross profit
  • Figure 30. GE Healthcare (United States) Revenue: by Geography 2021
  • Figure 31. Curium (France) Revenue, Net Income and Gross profit
  • Figure 32. Curium (France) Revenue: by Geography 2021
  • Figure 33. Lantheus Medical Imaging (United States) Revenue, Net Income and Gross profit
  • Figure 34. Lantheus Medical Imaging (United States) Revenue: by Geography 2021
  • Figure 35. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Bayer AG (Germany) Revenue: by Geography 2021
  • Figure 37. Bracco Imaging (Italy) Revenue, Net Income and Gross profit
  • Figure 38. Bracco Imaging (Italy) Revenue: by Geography 2021
  • Figure 39. Eczacıbaşı-Monrol Nuclear Products (Turkey) Revenue, Net Income and Gross profit
  • Figure 40. Eczacıbaşı-Monrol Nuclear Products (Turkey) Revenue: by Geography 2021
  • Figure 41. Nordion (Canada) Revenue, Net Income and Gross profit
  • Figure 42. Nordion (Canada) Revenue: by Geography 2021
  • Figure 43. Advanced Accelerator Applications (France) Revenue, Net Income and Gross profit
  • Figure 44. Advanced Accelerator Applications (France) Revenue: by Geography 2021
  • Figure 45. NTP Radioisotopes (South Africa) Revenue, Net Income and Gross profit
  • Figure 46. NTP Radioisotopes (South Africa) Revenue: by Geography 2021
  • Figure 47. Global Nuclear Medicine: by Type USD Million (2022-2027)
  • Figure 48. Global Nuclear Medicine: by Application USD Million (2022-2027)
  • Figure 49. Global Nuclear Medicine: by Procedural Volume Assessment USD Million (2022-2027)
  • Figure 50. Global Nuclear Medicine: by End Use USD Million (2022-2027)
  • Figure 51. South America Nuclear Medicine Share (%), by Country
  • Figure 52. Asia Pacific Nuclear Medicine Share (%), by Country
  • Figure 53. Europe Nuclear Medicine Share (%), by Country
  • Figure 54. MEA Nuclear Medicine Share (%), by Country
  • Figure 55. North America Nuclear Medicine Share (%), by Country
  • Figure 56. Global Nuclear Medicine: by Type K Unit (2022-2027)
  • Figure 57. Global Nuclear Medicine: by Application K Unit (2022-2027)
  • Figure 58. Global Nuclear Medicine: by Procedural Volume Assessment K Unit (2022-2027)
  • Figure 59. Global Nuclear Medicine: by End Use K Unit (2022-2027)
  • Figure 60. South America Nuclear Medicine Share (%), by Country
  • Figure 61. Asia Pacific Nuclear Medicine Share (%), by Country
  • Figure 62. Europe Nuclear Medicine Share (%), by Country
  • Figure 63. MEA Nuclear Medicine Share (%), by Country
  • Figure 64. North America Nuclear Medicine Share (%), by Country
  • Figure 65. Global Nuclear Medicine: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Cardinal Health (United States)
  • GE Healthcare (United States)
  • Curium (France)
  • Lantheus Medical Imaging (United States)
  • Bayer AG (Germany)
  • Bracco Imaging (Italy)
  • Eczacıbaşı-Monrol Nuclear Products (Turkey)
  • Nordion (Canada)
  • Advanced Accelerator Applications (France)
  • NTP Radioisotopes (South Africa)
Additional players considered in the study are as follows:
JSC Isotope (Russia) , NorthStar Medical Radioisotopes (United States) , Eckert & Ziegler (Germany) , Jubilant DraxImage (Canada)
Select User Access Type

Key Highlights of Report


Nov 2023 213 Pages 59 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nuclear Medicine Quantitative research analysis
Global Nuclear Medicine Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Nuclear Medicine market are Cardinal Health (United States), GE Healthcare (United States), Curium (France), Lantheus Medical Imaging (United States), Bayer AG (Germany), Bracco Imaging (Italy), Eczacıbaşı-Monrol Nuclear Products (Turkey), Nordion (Canada), Advanced Accelerator Applications (France) and NTP Radioisotopes (South Africa), to name a few.
"Alpha Radioimmunotherapy-Based Targeted Cancer Treatment" is seen as one of major influencing trends for Nuclear Medicine Market during projected period 2021-2027.
Tc-99 segment in Global market to hold robust market share owing to "Increasing Incidence and Prevalence of Target Conditions ".

Know More About Global Nuclear Medicine Report?

Have a Query? Click Here

Other Related Reports

Cataract Surgery Device Comprehensive Study by Type (Equipment, Consumables), Application (Ophthalmology Centers, Hospitals, Clinics), Products (Intraocular lens (IOL), Ophthalmic Viscoelastic Device...
$ 3650
Blood Glucose Monitoring Systems Comprehensive Study by Type (Data Management System, Insulin Delivery System, Combined System), Application (Hospitals, Clinics, Home Care Settings, Others), Product ...
$ 3650
Laparoscopic Trocars Comprehensive Study by Type (5mm, 10mm, 12mm, 15mm, Others), Application (General Surgery Procedure, Gynecology Procedure, Urology Procedure), End Users (Hospitals, Ambulatory Su...
$ 3350
Automated Suturing Devices Comprehensive Study by Type (Disposable Automated Suturing Devices, Reusable Automated Suturing Devices), Application (Cardiac, Orthopedic, Ophthalmic, Dental, Gynecologica...
$ 3450
Hemostat Comprehensive Study by Type (Gelatin-Based Hemostats, Thrombin-Based Hemostats, Collagen-Based Hemostats, Oxidized Regenerated Cellulose Based Hemostats, Combination Hemostats), Application ...
$ 2900
Skin Stapler Comprehensive Study by Type (Circular Skin Stapler, Hemorrhoidal Sin Stapler, Linear Skin Stapler, Reloadable Skin Stapler, Other), Application (Gastrointestinal Surgery, Gynecologic Sur...
$ 3650